Biosimilar Monoclonal Antibodies Market Research Report by Drug Class (Abciximab, Adalimumab, Bevacizumab, Infliximab, and Rituximab), by Application (Diagnostic, Protein Purification, and Therapeutic) - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from USD 4,147.48 Million in 2020 to USD 11,285.87 Million by the end of 2025.
2. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from EUR 3,636.59 Million in 2020 to EUR 9,895.66 Million by the end of 2025.
3. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from GBP 3,232.93 Million in 2020 to GBP 8,797.27 Million by the end of 2025.
4. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from JPY 442,641.60 Million in 2020 to JPY 1,204,488.86 Million by the end of 2025.
5. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from AUD 6,022.69 Million in 2020 to AUD 16,388.59 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Biosimilar Monoclonal Antibodies to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the Biosimilar Monoclonal Antibodies Market studied across Abciximab, Adalimumab, Bevacizumab, Infliximab, Rituximab, and Trastuzumab.
Based on Application, the Biosimilar Monoclonal Antibodies Market studied across Diagnostic, Protein Purification, and Therapeutic. The Diagnostic further studied across MAbs in Biochemical Analysis and MAbs in Diagnostic Imaging. The Therapeutic further studied across MAbs as Direct Therapeutic Agents and MAbs as Targeting Agents in Therapy.
Based on Geography, the Biosimilar Monoclonal Antibodies Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilar Monoclonal Antibodies Market including Allergan Plc, Biocon, BioXpress Therapeutics SA, Boehringer Ingelheim GmbH, Coherus BioSciences, Inc., Genor BioPharma Co. Ltd, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., and Reliance Life Sciences.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilar Monoclonal Antibodies Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biosimilar Monoclonal Antibodies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilar Monoclonal Antibodies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilar Monoclonal Antibodies Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilar Monoclonal Antibodies Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilar Monoclonal Antibodies Market?
6. What are the modes and strategic moves considered suitable for entering the Global Biosimilar Monoclonal Antibodies Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from USD 4,147.48 Million in 2020 to USD 11,285.87 Million by the end of 2025.
2. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from EUR 3,636.59 Million in 2020 to EUR 9,895.66 Million by the end of 2025.
3. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from GBP 3,232.93 Million in 2020 to GBP 8,797.27 Million by the end of 2025.
4. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from JPY 442,641.60 Million in 2020 to JPY 1,204,488.86 Million by the end of 2025.
5. The Global Biosimilar Monoclonal Antibodies Market is expected to grow from AUD 6,022.69 Million in 2020 to AUD 16,388.59 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Biosimilar Monoclonal Antibodies to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the Biosimilar Monoclonal Antibodies Market studied across Abciximab, Adalimumab, Bevacizumab, Infliximab, Rituximab, and Trastuzumab.
Based on Application, the Biosimilar Monoclonal Antibodies Market studied across Diagnostic, Protein Purification, and Therapeutic. The Diagnostic further studied across MAbs in Biochemical Analysis and MAbs in Diagnostic Imaging. The Therapeutic further studied across MAbs as Direct Therapeutic Agents and MAbs as Targeting Agents in Therapy.
Based on Geography, the Biosimilar Monoclonal Antibodies Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilar Monoclonal Antibodies Market including Allergan Plc, Biocon, BioXpress Therapeutics SA, Boehringer Ingelheim GmbH, Coherus BioSciences, Inc., Genor BioPharma Co. Ltd, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., and Reliance Life Sciences.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilar Monoclonal Antibodies Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biosimilar Monoclonal Antibodies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilar Monoclonal Antibodies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilar Monoclonal Antibodies Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilar Monoclonal Antibodies Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilar Monoclonal Antibodies Market?
6. What are the modes and strategic moves considered suitable for entering the Global Biosimilar Monoclonal Antibodies Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Application Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY DRUG CLASS
6.1. Introduction
6.2. Abciximab
6.3. Adalimumab
6.4. Bevacizumab
6.5. Infliximab
6.6. Rituximab
6.7. Trastuzumab
7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY APPLICATION
7.1. Introduction
7.2. Diagnostic
7.2.1. MAbs in Biochemical Analysis
7.2.1.1. Cancers
7.2.1.2. Hormonal disorders
7.2.1.3. Infectious diseases
7.2.1.4. Pregnancy
7.2.2. MAbs in Diagnostic Imaging
7.2.2.1. Atherosclerosis
7.2.2.2. Bacterial infections
7.2.2.3. Cancers
7.2.2.4. Cardiovascular diseases
7.2.2.5. Deep vein thrombosis (DVT)
7.3. Protein Purification
7.4. Therapeutic
7.4.1. MAbs as Direct Therapeutic Agents
7.4.2. MAbs as Targeting Agents in Therapy
8. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Allergan Plc
12.2. Biocon
12.3. BioXpress Therapeutics SA
12.4. Boehringer Ingelheim GmbH
12.5. Coherus BioSciences, Inc.
12.6. Genor BioPharma Co. Ltd
12.7. Intas Pharmaceuticals Limited
12.8. Novartis AG
12.9. Pfizer, Inc.
12.10. Reliance Life Sciences
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Application Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY DRUG CLASS
6.1. Introduction
6.2. Abciximab
6.3. Adalimumab
6.4. Bevacizumab
6.5. Infliximab
6.6. Rituximab
6.7. Trastuzumab
7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY APPLICATION
7.1. Introduction
7.2. Diagnostic
7.2.1. MAbs in Biochemical Analysis
7.2.1.1. Cancers
7.2.1.2. Hormonal disorders
7.2.1.3. Infectious diseases
7.2.1.4. Pregnancy
7.2.2. MAbs in Diagnostic Imaging
7.2.2.1. Atherosclerosis
7.2.2.2. Bacterial infections
7.2.2.3. Cancers
7.2.2.4. Cardiovascular diseases
7.2.2.5. Deep vein thrombosis (DVT)
7.3. Protein Purification
7.4. Therapeutic
7.4.1. MAbs as Direct Therapeutic Agents
7.4.2. MAbs as Targeting Agents in Therapy
8. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Allergan Plc
12.2. Biocon
12.3. BioXpress Therapeutics SA
12.4. Boehringer Ingelheim GmbH
12.5. Coherus BioSciences, Inc.
12.6. Genor BioPharma Co. Ltd
12.7. Intas Pharmaceuticals Limited
12.8. Novartis AG
12.9. Pfizer, Inc.
12.10. Reliance Life Sciences
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 82. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 83. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 84. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 85. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 86. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 87. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: SCORES
TABLE 88. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: BUSINESS STRATEGY
TABLE 89. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: PRODUCT SATISFACTION
TABLE 90. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RANKING
TABLE 91. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MERGER & ACQUISITION
TABLE 92. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 93. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 94. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: INVESTMENT & FUNDING
TABLE 95. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 96. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 82. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 83. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 84. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 85. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 86. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 87. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: SCORES
TABLE 88. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: BUSINESS STRATEGY
TABLE 89. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: PRODUCT SATISFACTION
TABLE 90. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RANKING
TABLE 91. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MERGER & ACQUISITION
TABLE 92. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 93. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 94. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: INVESTMENT & FUNDING
TABLE 95. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 96. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)
FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 VS 2025 (%)
FIGURE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 VS 2025 (USD MILLION)
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2025
FIGURE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, 2020 VS 2025 (USD MILLION)
FIGURE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2020 VS 2025 (USD MILLION)
FIGURE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, 2020 VS 2025 (USD MILLION)
FIGURE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, 2020 VS 2025 (USD MILLION)
FIGURE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2020 VS 2025 (USD MILLION)
FIGURE 35. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 36. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), 2020 VS 2025 (USD MILLION)
FIGURE 37. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, 2020 VS 2025 (USD MILLION)
FIGURE 38. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2020 VS 2025 (USD MILLION)
FIGURE 39. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, 2020 VS 2025 (USD MILLION)
FIGURE 40. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, 2020 VS 2025 (USD MILLION)
FIGURE 41. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 42. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 44. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 50. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 52. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 63. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 64. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 69. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 70. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 71. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 72. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 73. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 74. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 75. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 76. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 77. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 78. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY TYPE
FIGURE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)
FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 VS 2025 (%)
FIGURE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 VS 2025 (USD MILLION)
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2025
FIGURE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, 2020 VS 2025 (USD MILLION)
FIGURE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2020 VS 2025 (USD MILLION)
FIGURE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, 2020 VS 2025 (USD MILLION)
FIGURE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, 2020 VS 2025 (USD MILLION)
FIGURE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2020 VS 2025 (USD MILLION)
FIGURE 35. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 36. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), 2020 VS 2025 (USD MILLION)
FIGURE 37. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, 2020 VS 2025 (USD MILLION)
FIGURE 38. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2020 VS 2025 (USD MILLION)
FIGURE 39. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, 2020 VS 2025 (USD MILLION)
FIGURE 40. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, 2020 VS 2025 (USD MILLION)
FIGURE 41. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 42. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 44. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 50. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 52. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 63. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 64. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 69. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 70. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 71. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 72. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 73. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 74. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 75. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 76. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 77. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 78. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY TYPE
